Perspective Therapeutics Inc (CATX)

AMEX · Healthcare · Medical Devices · USA

Perspective Therapeutics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Perspective Therapeutics is a radiopharmaceutical development company creating cancer treatments using the alpha-emitting isotope Lead-212 to deliver targeted radiation to cancer cells. The company develops therapy candidates for neuroendocrine tumors, melanoma, and solid tumors, along with complementary imaging diagnostics to personalize treatment.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Perspective Therapeutics Inc stock.

Our verdict on CATX

Slightly overvalued: intrinsic value $0.73 per share, market price $0.86, margin of safety -17.4% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.73; the price of $0.86 is 17% above that value.

ETFs with the most weight in CATX

17 more funds hold it; the full list is part of the paid plan.

More on CATX

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CATX in Medical Devices

19 more in this industry show a wider margin of safety.

Is CATX undervalued or overvalued?

CATX is slightly overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.73; the price of $0.86 is 17% above that value.

What is the intrinsic value of CATX?

$0.73 per share (as of the 2026-11-17 close), against a market price of $0.86. That is a margin of safety of -17.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.